Recursion Pharmaceuticals (Recursion Pharmaceuticals) Interest Expense : $-0.10 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Recursion Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Recursion Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Recursion Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -96.34 Mil. Recursion Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -0.02 Mil. Recursion Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Recursion Pharmaceuticals Interest Expense Historical Data

The historical data trend for Recursion Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recursion Pharmaceuticals Interest Expense Chart

Recursion Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.64

-1.36

-2.95

-0.06

-0.10

Recursion Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial													-0.02	-0.03	-0.03	-0.03	-0.02

Recursion Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

Recursion Pharmaceuticals (NAS:RXRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Recursion Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-0.02 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-96.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $44.86 Mil.

Recursion Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Recursion Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101

Website

https://www.recursion.com

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Executives

Michael Secora	officer: Chief Financial Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani	officer: Chief Corp. Dev. Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson	director	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson	director, 10 percent owner, officer: Chief Executive Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson	officer: President and COO	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar	director	C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc	10 percent owner	P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert	other: Former 10% Owner	C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p.	other: Former 10% Owner	295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc	other: Former 10% Owner	920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc	other: Former 10% Owner	C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p.	other: Former 10% Owner	C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010